Direktif untuk semua produk yang mengandungi bisphosphonate (alendronate, clodronate, ibandronic acid, pamidronate, risedronate, zoledronic acid) : Pengemaskinian sisip bungkusan dengan risiko kesan advers berkaitan osteonecrosis of the external auditory

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive

Download/view the full document.



Go to Circular/Directive for other circulars or directives.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Wednesday 21 October 2020, 13:45:33.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language